Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis

Augusto Miravalle; Barry Hendin; Timothy L. Vollmer; Mrinalini Kala

doi:10.4137/CMT.S2057

Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis

Augusto Miravalle, Barry Hendin, Timothy L. Vollmer, Mrinalini Kala

Internal Medicine, Phoenix

Research output: Contribution to journal › Review article › peer-review

Abstract

Glatiramer acetate (GA; Copaxone^®) is a heterogeneous polymer of four amino acids. It is one of the therapies approved by the Food and Drug Administration in 1996 for treatment of relapsing remitting multiple sclerosis (RRMS). GA reduces the relapse rate for RRMS, and has a good safety profile and moderate efficacy. Preclinical and clinical studies reveal that GA plays a role in modulating the cells of the immune system as well as in neuroprotection. In this article, we review the role of GA in reducing the frequency of relapses in MS, as well as its efficacy, safety, and current place in therapy.

Original language	English (US)
Pages (from-to)	151-158
Number of pages	8
Journal	Clinical Medicine Insights: Therapeutics
Volume	3
DOIs	https://doi.org/10.4137/CMT.S2057
State	Published - 2011

Keywords

Glatiramer acetate
Multiple sclerosis
Relapse rate

ASJC Scopus subject areas

Pharmacology
Pharmaceutical Science

Access to Document

10.4137/CMT.S2057

Cite this

@article{3203c3f8de5542bca320279a28a01562,

title = "Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis",

abstract = "Glatiramer acetate (GA; Copaxone{\textregistered}) is a heterogeneous polymer of four amino acids. It is one of the therapies approved by the Food and Drug Administration in 1996 for treatment of relapsing remitting multiple sclerosis (RRMS). GA reduces the relapse rate for RRMS, and has a good safety profile and moderate efficacy. Preclinical and clinical studies reveal that GA plays a role in modulating the cells of the immune system as well as in neuroprotection. In this article, we review the role of GA in reducing the frequency of relapses in MS, as well as its efficacy, safety, and current place in therapy.",

keywords = "Glatiramer acetate, Multiple sclerosis, Relapse rate",

author = "Augusto Miravalle and Barry Hendin and Vollmer, {Timothy L.} and Mrinalini Kala",

year = "2011",

doi = "10.4137/CMT.S2057",

language = "English (US)",

volume = "3",

pages = "151--158",

journal = "Clinical Medicine Insights: Therapeutics",

issn = "1179-559X",

publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis

AU - Miravalle, Augusto

AU - Hendin, Barry

AU - Vollmer, Timothy L.

AU - Kala, Mrinalini

PY - 2011

Y1 - 2011

N2 - Glatiramer acetate (GA; Copaxone®) is a heterogeneous polymer of four amino acids. It is one of the therapies approved by the Food and Drug Administration in 1996 for treatment of relapsing remitting multiple sclerosis (RRMS). GA reduces the relapse rate for RRMS, and has a good safety profile and moderate efficacy. Preclinical and clinical studies reveal that GA plays a role in modulating the cells of the immune system as well as in neuroprotection. In this article, we review the role of GA in reducing the frequency of relapses in MS, as well as its efficacy, safety, and current place in therapy.

AB - Glatiramer acetate (GA; Copaxone®) is a heterogeneous polymer of four amino acids. It is one of the therapies approved by the Food and Drug Administration in 1996 for treatment of relapsing remitting multiple sclerosis (RRMS). GA reduces the relapse rate for RRMS, and has a good safety profile and moderate efficacy. Preclinical and clinical studies reveal that GA plays a role in modulating the cells of the immune system as well as in neuroprotection. In this article, we review the role of GA in reducing the frequency of relapses in MS, as well as its efficacy, safety, and current place in therapy.

KW - Glatiramer acetate

KW - Multiple sclerosis

KW - Relapse rate

UR - http://www.scopus.com/inward/record.url?scp=79957801110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957801110&partnerID=8YFLogxK

U2 - 10.4137/CMT.S2057

DO - 10.4137/CMT.S2057

M3 - Review article

AN - SCOPUS:79957801110

SN - 1179-559X

VL - 3

SP - 151

EP - 158

JO - Clinical Medicine Insights: Therapeutics

JF - Clinical Medicine Insights: Therapeutics

ER -

Glatiramer acetate in the reduction of relapse frequency in multiple sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this